Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study of ORIC-114 in Combination With Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

NCT06816992 is registered in ClinicalTrials.gov with ORIC Pharmaceuticals as lead sponsor.

NCT NCT06816992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06816992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study of ORIC-114 in Combination With Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Lead sponsor
ORIC Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
February 27, 2025
Completion date
December 31, 2027
Enrollment
76 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon 20 insertion mutations, egfr-mutated nsclc, nsclc, solid tumors